Clinical trial · Interventional
Study on Therapy of Non-invasive Prolactinoma
Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma
NCT03353025CI-TRIAL-00030524TNAPAunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prolactinoma | Lactotroph Pituitary Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dopamine agonist treatment | Drug | — | UNRESOLVED |
| transsphenoidal surgery treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- transsphenoidal surgery treatment
- description
- Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
- interventionNames
- Procedure: transsphenoidal surgery treatment
- type
- EXPERIMENTAL
- label
- dopamine agonist treatment
- description
- Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
- interventionNames
- Drug: dopamine agonist treatment
Primary outcomes (1)
- measure
- Endocrine remission rate
- timeFrame
- five-year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: non-invasive prolactionma Exclusion Criteria: invasive prolactioma
References
Publications (0)
Data not yet available
No reference posted for this study.